Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Targeting Gut Disease
Bologna, Emilia-Romagna, Italytgd.care ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Targeting Gut Disease has developed several proprietary nutraceutical ingredients—such as BIOintestil®, Eugedin Complex®, Limenorm®, Clovedin®, and Algistat®—with published clinical studies supporting efficacy in gut health modulation and related indications. BIOintestil® was a 2025 NutraIngredients Awards finalist for "Ingredient of the Year – Microbiome Modulation" and has been evaluated in randomized double-blind placebo-controlled trials[1][4][6]. Ongoing studies include open-label interventional trials for fibromyalgia with Algistat®[1].
- Therapeutic areas
- RheumatologyGastroenterologyMetabolic DisordersInfectious Diseases
- Modalities
- Live biotherapeutic product therapyMicrobial therapyNutraceuticals (dietary supplements based on natural ingredients and essential oils)
- Industry
- Food & Nutrition
02
Partnerships
University of Bologna (foundational partner)University of Siena (collaboration on Algistat)Italian Association of Fibromyalgia Patients CFU – Comitato Fibromialgici Uniti
Beyond the preview
Go deeper on Targeting Gut Disease.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Targeting Gut Disease.